S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Price, News & Analysis

$2.28
+0.16 (+7.55%)
(As of 02/21/2024 ET)
Today's Range
$2.04
$2.29
50-Day Range
$1.71
$2.28
52-Week Range
$1.32
$3.97
Volume
1.29 million shs
Average Volume
788,979 shs
Market Capitalization
$574.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Lyell Immunopharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
185.1% Upside
$6.50 Price Target
Short Interest
Healthy
9.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.25 out of 5 stars

Medical Sector

538th out of 932 stocks

Pharmaceutical Preparations Industry

249th out of 431 stocks


LYEL stock logo

About Lyell Immunopharma Stock (NASDAQ:LYEL)

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL Stock Price History

LYEL Stock News Headlines

Lyell Immunopharma Inc (LYEL)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Heather D. Lyell
Why Lyell Immunopharma Shares Are Rising Today
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Lyell Immunopharma reports Q3 results
Lyell Immunopharma Shares Up 8% on Cellares Collaboration
See More Headlines
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/21/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
274
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$8.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+185.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-183,120,000.00
Net Margins
-391.93%
Pretax Margin
-391.93%

Debt

Sales & Book Value

Annual Sales
$84.68 million
Book Value
$3.34 per share

Miscellaneous

Free Float
191,420,000
Market Cap
$574.26 million
Optionable
Optionable
Beta
-0.85
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Richard D. Klausner M.D. (Age 72)
    Founder & Executive Chairman
    Comp: $80k
  • Dr. Lynn Seely M.D. (Age 65)
    Ph.D., President, CEO & Director
    Comp: $430.69k
  • Mr. Charles W. Newton (Age 53)
    Chief Financial Officer
    Comp: $1.72M
  • Mr. Stephen J. Hill (Age 54)
    Chief Operating Officer
    Comp: $1.04M
  • Dr. Gary Lee Ph.D. (Age 47)
    Chief Scientific Officer
    Comp: $639.91k
  • Ms. Elizabeth Homans (Age 58)
    Consultant
    Comp: $1.99M
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D. (Age 64)
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Ms. Ellen Rose
    Senior Vice President of Communications & Investor Relations














LYEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LYEL shares.
View LYEL analyst ratings
or view top-rated stocks.

What is Lyell Immunopharma's stock price target for 2024?

2 analysts have issued 1-year price objectives for Lyell Immunopharma's stock. Their LYEL share price targets range from $5.00 to $8.00. On average, they anticipate the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 185.1% from the stock's current price.
View analysts price targets for LYEL
or view top-rated stocks among Wall Street analysts.

How have LYEL shares performed in 2024?

Lyell Immunopharma's stock was trading at $1.94 at the beginning of the year. Since then, LYEL stock has increased by 17.5% and is now trading at $2.28.
View the best growth stocks for 2024 here
.

Are investors shorting Lyell Immunopharma?

Lyell Immunopharma saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 10,840,000 shares, a drop of 30.6% from the January 15th total of 15,620,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is currently 8.2 days. Approximately 9.4% of the shares of the stock are short sold.
View Lyell Immunopharma's Short Interest
.

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our LYEL earnings forecast
.

When did Lyell Immunopharma IPO?

(LYEL) raised $425 million in an initial public offering on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.40%), WuXi AppTec Co. Ltd. (3.25%), Price T Rowe Associates Inc. MD (2.64%), Price T Rowe Associates Inc. MD (2.64%), Northern Trust Corp (0.59%) and Massachusetts Financial Services Co. MA (0.54%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends
.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYEL) was last updated on 2/22/2024 by MarketBeat.com Staff